TY  - BOOK
AU  - Ahmed Bahaa Eldin Abbas 
AU  - Maissa Elsaid Elraziky , 
AU  - Mohammad Elsayed Soliman , 
AU  - Walied Khalid Alhossary , 
TI  - A randomized study comparing moxifloxacin, omeprazole, nitazoxanide, and doxycycline versus classic triple therapy for the eradication of helicobacter pylori / 
PY  - 2019///
CY  - Cairo : 
PB  - Ahmed Bahaa Eldin Abbas , 
KW  - Helicobacter pylori
KW  - Moxifloxacin
KW  - Treatment
N1  - Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine; Issued also as CD
N2  - Introduction:Helicobacter pylori infection is a global concern with rising antimicrobial resistance and declining cure rates which has led to an increased demand for a more efficacious, yet tolerable, therapy.  Aim: To evaluate the efficacy and safety of the two regimens (Amoxicillin, clarithromycin and omeprazole for 14 days vs moxifloxacin, doxycycline, nitazoxanide and omeprazole for 14 days) as a first-line treatment for Helicobacter pylori (H. pylori) infection.  Patients &Methods: From September 2018 to April 2019, 90 patients with confirmed H. pylori infection were randomized into two groups.The First group (triple group)(n = 44) received amoxicillin 1000 mg, clarithromycin500 mg and Omeprazole 40 mg twice a day for 14 days, the Second group (MOND group) (n = 46) received Moxifloxacin 400 mg, Doxycycline 100 mg once daily, Nitazoxanide 500 mg and Omeprazole 40 mg twice a day for 14 days. Successful eradication of H. pylori infection was defined as a negative Stool antigen test 6 weeks after the end of treatment. Patient compliance was defined as 2good3 if drug intake was at least 90%.Follow up of patient'sadherenceto treatment, adverse event rates and dyspepsia improvement was done 6 weeks after theend of treatment
UR  - http://172.23.153.220/th.pdf
ER  -